IMPAVIDO Drug Patent Profile
✉ Email this page to a colleague
When do Impavido patents expire, and what generic alternatives are available?
Impavido is a drug marketed by Knight Theraps and is included in one NDA.
The generic ingredient in IMPAVIDO is miltefosine. One supplier is listed for this compound. Additional details are available on the miltefosine profile page.
Summary for IMPAVIDO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 11 |
| Patent Applications: | 4,110 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in IMPAVIDO? | IMPAVIDO excipients list |
| DailyMed Link: | IMPAVIDO at DailyMed |
Recent Clinical Trials for IMPAVIDO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kenya Medical Research Institute | Phase 3 |
| The Institute of Endemic Diseases (IEND), University of Khartoum | Phase 3 |
| Makerere University | Phase 3 |
Pharmacology for IMPAVIDO
| Drug Class | Antileishmanial |
Anatomical Therapeutic Chemical (ATC) Classes for IMPAVIDO
US Patents and Regulatory Information for IMPAVIDO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Knight Theraps | IMPAVIDO | miltefosine | CAPSULE;ORAL | 204684-001 | Mar 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
